Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Ward, Paul V. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S253000, C544S283000, C514S266100
Reexamination Certificate
active
07863281
ABSTRACT:
The present invention relates to bicyclic heterocycles of general formulawhereinRa, Rb, Rc, A, B, C, D, E and X are defined as in claim1, the tautomers, the stereoisomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases, as well as benign prostatic hyperplasia (BPH), diseases of the lungs and respiratory tract, and the preparation thereof.
REFERENCES:
patent: 6627634 (2003-09-01), Himmelsbach et al.
patent: 6740651 (2004-05-01), Himmelsbach et al.
patent: 7019012 (2006-03-01), Himmelsbach et al.
patent: 7220750 (2007-05-01), Himmelsbach et al.
patent: 2001/0044435 (2001-11-01), Himmelsbach et al.
patent: 2004/0044014 (2004-03-01), Himmelsbach et al.
patent: 2005/0159436 (2005-07-01), Himmelsbach et al.
patent: 2007/0185091 (2007-08-01), Himmelsbach et al.
patent: 2008/0103161 (2008-05-01), Himmelsbach et al.
patent: 2010/0069414 (2010-03-01), Himmelsbach et al.
patent: 2361174 (2000-09-01), None
patent: 2403152 (2001-10-01), None
patent: 2417042 (2002-03-01), None
patent: 2432428 (2002-06-01), None
patent: 2375295 (2002-09-01), None
patent: 2417907 (2003-01-01), None
patent: 2484395 (2003-10-01), None
patent: 19908567 (2000-08-01), None
patent: 10017539 (2001-10-01), None
patent: 9738983 (1997-10-01), None
patent: 9909016 (1999-02-01), None
patent: WO/00/51991 (2000-02-01), None
patent: 0018740 (2000-04-01), None
patent: 0051991 (2000-09-01), None
patent: 0078735 (2000-12-01), None
patent: WO 00/78735 (2000-12-01), None
patent: 0177104 (2001-10-01), None
patent: WO 01/77104 (2001-10-01), None
patent: 0218370 (2002-03-01), None
patent: 0218376 (2002-03-01), None
patent: 0250043 (2002-06-01), None
patent: 03089439 (2003-10-01), None
Tsou et al, 6-substituted-4-(3-bromophenylamino) quinazolines . . . , J. Med. Chem. 2001, 44, 2719-2734.
Pinedo et al., “Translational Research . . . ”, The Oncologist 2000,, 5 (suppl1): 1-2 (www.The Oncologist .com).
McMahon, Gerald, “VEGF Receptor Signaling in Tumor Angiogenesis”, The Oncologist 2000; 5(suppl 1): 3-10 (www.The Oncologist.com).
Tsou, et al., “6-Substituted-4-(3-bromophenylamino) quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity”, J. Med. Chem, 2001, vol. 44, p. 2719-2734.
International Search Report for PCT/EP2003/03828 mailed Jul. 30, 2003.
Himmelsbach Frank
Jung Birgit
Solca Flavio
Boehringer Ingelheim Pharma GmbH & Co. KG
Dow David A.
Lazer Edward S.
Morris Michael P.
Ward Paul V.
LandOfFree
Bicyclic heterocycles, pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic heterocycles, pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic heterocycles, pharmaceutical compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2626864